Page 1

June 16 , 2021 MEDEXUS PHARMA Medexus Revenue Increases 43.5 % to a Record US $ 79.7 Million for Fiscal 2021 Transformative licensing agreement for treosulfan in the U.S. completed February 2 , 2021 Cash and cash equivalents of $ 18.7 million and available liquidity of $ 24.8 million at March 31 , 2021 Management to host conference call at 8:00 AM Eastern Time on June 17th , 2021 TORONTO and CHICAGO , June 16 , 2021 ( GLOBE NEWSWIRE ) Medexus Pharmaceuticals Inc. ( the “ Company " or " Medexus ” ) ( TSX : MDP ) ( OTCQX : MEDXF ) today announced its financial and operating results for the fourth quart and fiscal year ended March 31 , 2021. As greater than 75 % of the Company's revenue is now derived from the U.S. , the Company's results have been reported in U.S. dollars , which will be the Company's reporting currency going forward . All dollar amounts below are in U.S. dollars unless specified otherwise . Fourth Quarter Fiscal 2021 Financial Highlights * : Revenue of $ 17.6 million in the fourth quarter , compared to $ 18.8 million for the same period last year . While patient unit demand for IXINITY® continued to grow during the fourth quarter , net sales were lower as pharmacies and wholesalers worked through inventory on hand . • Adjusted EBITDA decreased to $ ( 1.6 ) million compared to $ 3.1 million for the same period last year , due primarily to an increase in Selling and Administrative Expenses as the company prepares for the launch of treosulfan and an increase in Research & Development spending for the IXINITY® pediatric study . Cash provided by operating activities of $ 4.2 million , compared to cash used by operating activities of $ 1.3 million for the same period last year . • Net loss of $ 10.5 million compared to $ 1.6 million for the same period last year . • Adjusted Net Loss of $ 5.2 million compared to $ 5.1 million for the same period last year . Fiscal 2021 Financial Highlights * : • Revenue of $ 79.7 million in fiscal 2021 versus $ 55.5 million in fiscal 2020 . • Adjusted EBITDA increased to $ 8.2 million for fiscal 2021 compared to $ 4.4 million for fiscal 2020 . • Net loss of $ 28.3 million in fiscal 2021 compared to $ 4.7 million in fiscal 2020 . • Adjusted Net Loss of $ 7.6 million in fiscal 2021 compared to $ 13.9 million for fiscal 2020 . • Cash provided by operating activities of $ 5.0 million , compared to cash used by